Axogen Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.20
Dividend & YieldN/A$ (N/A)
Beta 0.54
Market capitalization 443.16M
Operating cash flow -18.94M
ESG Scores unknown

Company description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Sector: Healthcare - Industry: Medical Devices

Financial Ratios
Quick Ratio4.54
Working Capital-0.26
Return On Equity-0.24
Debt To Equity0.45
Fixed Asset Ratio0.02
Fixed Interest Cover-18.74

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 3.65M 2.89M 4.95M -273k
Total Cashflows From Investing Activities -98.19M 27.27M -16.96M -23.65M
Net Borrowings -26.75M 29k 34.99M 14.98M
Total Cash From Financing Activities 109.84M 4.03M 40.47M 20.45M
Change To Operating Activities -192k -2.44M -3.61M 1.97M
Issuance Of Stock 136.85M 4M 6.8M 5.47M
Net Income -22.4M -29.14M -23.79M -26.98M
Change In Cash -6.21M 11.43M 13.88M -16.6M
Effect Of Exchange Rate
Total Cash From Operating Activities -17.86M -19.87M -9.63M -13.4M
Depreciation 851k 2.88M 3.46M 4.74M
Change To Account Receivables -5.11M -2.14M -635k -499k
Other Cashflows From Financing Activities -257k -642k -642k
Change To Netincome 11.27M 11.84M 10.68M 14.29M
Capital Expenditures -6.28M -4.66M -21.91M -27.81M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 11.77M 17.51M 17.85M 24.18M
Income Before Tax -22.4M -29.14M -23.79M -26.98M
Net Income -22.4M -29.14M -23.79M -26.98M
Selling General Administrative 79.74M 103.15M 96.06M 105.67M
Gross Profit 71.01M 89.36M 90.72M 104.43M
Ebit -20.5M -31.3M -23.18M -25.42M
Operating Income -20.5M -31.3M -23.18M -25.42M
Interest Expense -1.21M -40k -1.05M -1.36M
Income Tax Expense
Total Revenue 83.94M 106.71M 112.3M 127.36M
Cost Of Revenue 12.92M 17.35M 21.58M 22.93M
Total Other Income ExpenseNet -1.9M 2.17M -604k -1.57M
Net Income From Continuing Ops -22.4M -29.14M -23.79M -26.98M
Net Income Applicable To Common Shares -22.4M -29.14M -23.79M -26.98M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 13.19M 22.49M 78.23M 95.47M
Total Stockholder Equity 146.98M 132.15M 123.15M 112.55M
Other Current Liabilities 18k
Total Assets 160.17M 154.64M 201.38M 208.02M
Common Stock 389k 396k 406k 417k
Other Current Assets 6M 6.3M 7.08M 6.49M
Retained Earnings -150.73M -179.86M -203.65M -230.63M
Treasury Stock
Cash 24.29M 35.72M 48.77M 32.76M
Total Current Liabilities 13.04M 20.88M 22.83M 24.29M
Other Stockholder Equity
Property, Plant, and Equipment 8.04M 18.11M 54.08M 78.12M
Total Current Assets 150.95M 135.02M 145.25M 127.05M
Net Tangible Assets 145.8M 130.64M 121.09M 109.69M
Net Receivables 15.32M 17.19M 17.62M 18.16M
Accounts Payable 4.52M 8.26M 4.6M 5.92M


Insider Transactions

Here are the insider transactions of stock shares related to Axogen Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MARIANI PETER JSale at price 11.88 per share.D2022-11-16Chief Financial Officer10.65k
FREITAG GREGORY GENESale at price 12.74 per share.D2022-11-14Director13k
FREITAG GREGORY GENESale at price 12.50 per share.D2022-11-08Director13k
FREITAG GREGORY GENESale at price 9.70 per share.D2022-08-10Director8.89k
FREITAG GREGORY GENESale at price 10.37 - 10.64 per share.D2022-08-08Director37.05k
FREITAG GREGORY GENEConversion of Exercise of derivative security at price 3.38 per share.D2022-07-25Director83k
MARIANI PETER JStock Award(Grant) at price 0.00 per share.D2022-07-18Chief Financial Officer3.71k
ZADEREJ KAREN LStock Award(Grant) at price 0.00 per share.D2022-07-18Chief Executive Officer22.08k
DEVINNEY ERICK WAYNEStock Award(Grant) at price 0.00 per share.D2022-07-18Officer1.58k
MARTINEZ MARIA DStock Award(Grant) at price 0.00 per share.D2022-07-18Officer2.57k
DONOVAN MICHAEL PATRICKStock Award(Grant) at price 0.00 per share.D2022-07-18Officer2.57k
SCOPELIANOS ANGELOStock Award(Grant) at price 0.00 per share.D2022-07-18Officer2.57k
BILLET ISABELLEStock Award(Grant) at price 0.00 per share.D2022-07-18Officer2.57k
SANDBERG ERICStock Award(Grant) at price 0.00 per share.D2022-07-18Officer4.41k
FREITAG GREGORY GENED2022-06-01Director3.04k
GOLD MARK STEPHEND2022-06-01Director3.04k
THOMAS PAUL GStock Award(Grant) at price 0.00 per share.D2022-06-01Director3.04k
THOMAS PAUL GConversion of Exercise of derivative security at price 9.29 per share.D2022-06-01Director3.04k
NEELS GUIDO JD2022-06-01Director3.04k
WENDELL AMY MCBRIDED2022-06-01Director3.04k
LEVINE ALAN M.D2022-06-01Director3.04k
OTTINGER BRADLEYD2022-06-01General Counsel15.5k
BLACKFORD QUENTIN SD2022-03-30Director3.04k
MARIANI PETER JD2022-03-16Chief Financial Officer11k
FRIEDMAN MARK LOUISD2022-03-16Officer6k
ZADEREJ KAREN LD2022-03-16Chief Executive Officer25.95k
DEVINNEY ERICK WAYNED2022-03-16Officer6k
MARTINEZ MARIA DD2022-03-16Officer12.87k
DONOVAN MICHAEL PATRICKD2022-03-16Officer6k
SCOPELIANOS ANGELOD2022-03-16Officer11k
BILLET ISABELLED2022-03-16Officer8.5k
SANDBERG ERICD2022-03-16Officer6k
OTTINGER BRADLEYD2022-03-16General Counsel2.56k
DONOVAN MICHAEL PATRICKConversion of Exercise of derivative security at price 5.09 - 5.45 per share.D2022-02-22Officer15k
MARIANI PETER JStock Award(Grant) at price 0.00 per share.D2022-02-15Chief Financial Officer3.16k
FRIEDMAN MARK LOUISStock Award(Grant) at price 0.00 per share.D2022-02-15Officer1.18k
ZADEREJ KAREN LStock Award(Grant) at price 0.00 per share.D2022-02-15Chief Executive Officer13.98k
DEVINNEY ERICK WAYNEStock Award(Grant) at price 0.00 per share.D2022-02-15Officer1.18k
MARTINEZ MARIA DStock Award(Grant) at price 0.00 per share.D2022-02-15Officer1.32k
DONOVAN MICHAEL PATRICKStock Award(Grant) at price 0.00 per share.D2022-02-15Officer675
SCOPELIANOS ANGELOStock Award(Grant) at price 0.00 per share.D2022-02-15Officer1.32k
BILLET ISABELLEStock Award(Grant) at price 0.00 per share.D2022-02-15Officer1.32k
SANDBERG ERICStock Award(Grant) at price 0.00 per share.D2022-02-15Officer2.53k
MARIANI PETER JD2021-12-27Chief Financial Officer2.62k
FRIEDMAN MARK LOUISD2021-12-27Officer1.15k
ZADEREJ KAREN LD2021-12-27Chief Executive Officer4.4k
DEVINNEY ERICK WAYNED2021-12-27Officer750
MARTINEZ MARIA DD2021-12-27Officer1.15k
DONOVAN MICHAEL PATRICKD2021-12-27Officer1.15k
SCOPELIANOS ANGELOD2021-12-27Officer1.15k
BILLET ISABELLED2021-12-27Officer1.15k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Axogen Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Axogen Inc

Here is the result of two systematic investment strategies applied to Axogen Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Axogen Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Axogen Inc:

Axogen Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -11.76% on the backtest period.

Performance at glance

Performance

-11.76 %

Latent gain

-205.11 $

Invested capital

1743.99 $

Annualized return

-2.87 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Axogen Inc

This is the result of two momentum investment strategies applied to Axogen Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Axogen Inc

The following chart shows all the entries opened by the momentum investment system on Axogen Inc:

Axogen Inc momentum entries
  • The first momentum investment strategy would give -9.63% of return on Axogen Inc. That represents -336.62$ of latent gain with 3496.82$ of employed capital.
  • The second momentum investment strategy would give -12.12% of return on Axogen Inc. That represents -305.14$ of latent gain with 2517.28$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-9.63 %

Latent gain

-336.62 $

Invested capital

3496.82 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-12.12 %

Latent gain

-305.14 $

Invested capital

2517.28 $

Annualized return

-3.35 %

Momentum equity curve on Axogen Inc

The following chart shows the equity curve of the two momentum strategies applied to Axogen Inc:

Axogen Inc momentum equity

Note: the dividends potentially given by Axogen Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Axogen Inc

The following chart shows the employed capital evolution of the two momentum strategies on Axogen Inc since the beginning:

Axogen Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Axogen Inc

Buy the dip entry openings on Axogen Inc

Axogen Inc

The performance achieved by the robo-advisor on Axogen Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Axogen Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Axogen Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Axogen Inc

The following chart shows the result of the investment strategy applied to Axogen Inc:

Axogen Inc

Note: the dividends potentially given by Axogen Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Axogen Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Axogen Inc:

Axogen Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Axogen Inc

In this section, I will compare the three previous investment strategies applied to Axogen Inc.

Equity curve comparison on Axogen Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Axogen Inc investment strategy comparison

Employed capital comparison on Axogen Inc

Axogen Inc investment comparison

Performance comparison on Axogen Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -11.76% -205.11$ 1743.99$ -2.87%
Momentum 1 quarter -9.63% -336.62$ 3496.82$ -2.49%
Momentum 2 quarters -12.12% -305.14$ 2517.28$ -3.35%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-2.87 %

Momentum 1Q

-3.35 %

Momentum 2Q

-3.35 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Axogen Inc:


Company information

Company name Axogen Inc
Country United States
City Alachua
Address 13631 Progress Boulevard
Phone 386 462 6800
Website www.axogeninc.com
FullTime employees 428
Industry Medical Devices
Sector Healthcare
Exchange XNAS
Ticker AXGN
Market www.nasdaq.com

Axogen Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown